Business Wire

DENSE-AIR

5.6.2019 17:19:03 CEST | Business Wire | Press release

Share
Dense Air and Dublin City Council win Small Cell Forum Award for Dublin Docklands 5G Neutral Host Deployment Model & Announces 5G Smart Cities Innovation Accelerator Program

Dense Air & Dublin City Council win the 2019 Small Cell Forum Award for Social Impact – ‘Promoting Small Cells for Social/Economic/Environmental Development’. It follows successful completion of the first phase of a ground breaking 5G research and development network in Dublin’s Docklands delivered as part of the Dublin City Council (DCC) ‘Smart Docklands’ initiative.

This strategic partnership between Dense Air and DCC announced in January 2018 was intended to provide a framework for the large-scale deployment of a “pervasive” 5G connectivity solution across Dublin, and also intended to develop a blue print for future deployments globally. The initial findings have demonstrated that Neutral Host Small Cells can provide unrivalled benefits to cities and mobile operators.

Working with City council departments, national agencies, building owners and the Science Foundation Ireland CONNECT Research Centre for future networks based in TCD, Dense Air have focused on understanding how best to deploy small cells on city owned street assets build neutral-host infrastructure that can be used simultaneously, by multiple mobile network providers and private networks to simplify the small cell installation process. Having an efficient, affordable, scalable and repeatable processes, are key factors in deploying 5G small cells networks, where densification and improved indoor performance will require access to city street assets including lamp posts and traffic lights.

The judging panel stated that: “There are many interesting smart city projects involving small cells but the collaboration between Dense Air and Dublin City Council stands out for the variety of services supported, and well-quantified benefits to citizens, businesses and visitors The judges were also impressed by the neutral host model, which they believe will be very significant in lowering barriers to deployment of large networks.”

Jamie Cudden, Smart City Program Manager said:“Dublin City Council is delighted to be recognised by the Small Cell Forum for our collaboration with Dense Air. The delivery of this project was only possible through collaboration with the CONNECT research centre for future networks, local building owners and the engagement of our wider Smart Docklands partner network.

“Pervasive connectivity offers cities a clear competitive advantage and we are now ideally placed to provide a perfect live 5G test environment for companies to work with us to trial services that can help us solve different challenges. Furthermore Dublin is now providing other cities globally a template for how they can realise the future 5G opportunity.”

Paul Senior , CEO of Dense Air said “We are absolutely thrilled to have received two awards at the 2019 Small Cell Forum World Summit in London. These awards recognise Dense Air’s unique neutral host business model based on densification using small cells, and deployment and engagement we have with cities, namely Dublin City Council.”

Building on the success of this project, Dublin City Council will host the prestigious Harvard TECH Innovators Forum in partnership with Dense Air from 7-9th October 2019; Bringing together city technology leaders from across the world to share emerging best practice for 5G deployments and showcasing the Dublin Docklands 5G Pervasive Network.

Dr. David Ricketts, Innovation Fellow in the Technology in Entrepreneurship Center at Harvard (TECH) comments that, ”We are delighted to bring together cities in Dublin to share best practice experiences on how they can manage disruptive technologies in a way that will allow us to build better communities for everyone. This unique gathering will bring the top global city technology leaders together to better understand how cities can best leverage and lead on the 5G opportunity.”

https://theinnovatorsforum.org/

Dense Air is headquartered in London, UK and has offices in the target launch markets of Ireland, Belgium, Portugal, Australia & New Zealand. Dense Air provides a unique “carrier of carriers” wholesale neutral host small cell services to deliver cost-effective densification to existing mobile carriers or service providers. Dense Air is conducting extensive trials and proof-of-concepts in 2019 and will offer commercial services in 2020. Dense Air provides small cell services in Ireland based on licensed 3.4-3.8GHz radio spectrum awarded by Ireland regulator in 2017.

http://www.denseair.net/

Dublin City Council (DCC) is leading a series of innovative partnerships with world-leading technology companies through its Smart Dublin initiative. The Smart Docklands district was set up in February 2018 to deliver and fast-track smart city projects and deployments and understand the different types of connectivity and networks that would enable future cities. This was established in partnership with CONNECT, a national research centre for connectivity and future networks. Smart Docklands was a first of its kind in Ireland, where the municipality and academia have created a dedicated Project Management Office (PMO) to play an independent role amongst multiple stakeholders, from global technology companies to local residents’ groups, from academic institutions to international property developers, innovative start-ups and SMEs to fast track emerging smart city opportunities. http://smartdocklands.ie/

Contact:

Dense Air Paul Coffey Tel: 01895 467100 www.denseair.net

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye